Author

S. Yazdani

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:protein structure· 1

Frequent Co-Authors

M. Schapira· 2 shared A. Aimon· 1 shared A. Douangamath· 1 shared A. M. Chinnaiyan· 1 shared A. Parolia· 1 shared D. FearoniD· 1 shared F. Su· 1 shared F. von DelftiD· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

M. Schapira

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

PIKfyve controls dendritic cell function and tumor immunity

J. E. Choi, Y. Qiao, I. Kryczek, J. Yu, J. Gurkan, Y. Bao, M. Gondal, J. C.-Y. Tien, T. Maj, S. Yazdani, A. Parolia, H. Xia, J. Zhou, S. Wei, S. Grove, , A. M. Chinnaiyan

This study shows that PIKfyve inhibition enhances dendritic cell function and improves immunotherapy efficacy in tumor models.

bioRxiv · Feb 28, 2024Cancer Biology

Structure, Mechanism and Crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase

J. A. Newman, A. Douangamath, S. Yazdani, Y. Yosaatmadja, A. Aimon, J. Brandao-Neto, L. Dunnett, T. Gorrie-Stone, R. Skyner, D. Fearon, M. Schapira, F. von Delft, O. Gileadi

This study presents crystal structures of SARS-CoV-2 NSP13 and identifies druggable pockets, revealing potential targets for antiviral drug development through fragment screening.

Nature Communications · Aug 11, 2021Peer-reviewedBiochemistry

The SARS-CoV-2 replication-transcription complex is a priority target for broad-spectrum pan-coronavirus drugs

S. Yazdani, N. De Maio, Y. Ding, V. Shahani, N. Goldman, M. Schapira

The paper identifies two highly conserved druggable sites in the SARS-CoV-2 replication-transcription complex as potential targets for broad-spectrum antiviral drugs.

bioRxiv · Mar 23, 2021Pharmacology & Toxicology